Valuation : Moderna, Inc.

Market Cap 5.97TCr 5.13TCr 4.8TCr 4.4TCr 8.28TCr 5,70700Cr 8.31TCr 57TCr 22TCr 2,87600Cr 22TCr 22TCr 9,51900Cr P/E 2026 *
-17.7x
P/E 2027 * -30.1x
Enterprise Value 5.61TCr 4.82TCr 4.51TCr 4.13TCr 7.78TCr 5,35800Cr 7.8TCr 53TCr 21TCr 2,70000Cr 21TCr 21TCr 8,93700Cr EV / Sales 2026 *
26.6x
EV / Sales 2027 * 23.2x
Free-Float
92.68%
Yield 2026 *
-
Yield 2027 * -
1 day-4.91%
1 week-18.13%
Current month+160.43%
1 month+164.05%
3 months+203.57%
6 months+176.10%
Current year+384.13%
1 week 130
Extreme 130
161.37
1 month 52.66
Extreme 52.6601
176.66
Current year 29.81
Extreme 29.81
176.66
1 year 22.28
Extreme 22.28
176.66
3 years 22.28
Extreme 22.28
176.66
5 years 22.28
Extreme 22.28
464.85
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 63 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Date Insider Type Main position Quantity % Market Cap.
06/08/26 Fiscal year

Chief Executive Officer

5,04,938 0.1273%
15/07/26 Fiscal year

Chairperson

1,60,008 0.0403%
08/07/26 Free

Director

14,766 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
-4.60%-18.13%+477.32%+27.55% 5.97TCr
-0.87%-3.94%+37.45%-2.73% 8.14TCr
+0.84%+4.44%-19.19%-35.11% 5.92TCr
+0.76%+3.53%+0.08%+36.18% 5.33TCr
+0.41%+1.88%+11.09%+171.67% 4.91TCr
+0.19%-0.03%+62.01%-16.23% 3.27TCr
-0.30%-0.57%+52.07%+100.03% 2.6TCr
-2.00%+9.52%+12.38%+218.34% 2.44TCr
+0.78%+0.47%+61.53%+123.40% 1.69TCr
-4.68%+2.52%-9.33%+752.25% 1.56TCr
Average -0.98%-0.46%+68.54%+137.54% 4.18TCr
Weighted average by Cap. -0.87%-1.34%+85.00%+73.99%

Financials

2026 *2027 *
Net sales 210.6Cr 180.78Cr 169.25Cr 154.98Cr 291.95Cr 20TCr 292.78Cr 2TCr 783.47Cr 10TCr 790.71Cr 773.63Cr 34TCr 247.57Cr 212.52Cr 198.96Cr 182.19Cr 343.2Cr 24TCr 344.18Cr 2.36TCr 921Cr 12TCr 929.51Cr 909.44Cr 39TCr
Net income -331.71Cr -284.74Cr -266.58Cr -244.1Cr -459.84Cr -32TCr -461.14Cr -3.16TCr -1.23TCr -16TCr -1.25TCr -1.22TCr -53TCr -193.43Cr -166.04Cr -155.45Cr -142.34Cr -268.15Cr -18TCr -268.91Cr -1.84TCr -719.58Cr -9.31TCr -726.24Cr -710.55Cr -31TCr
Net Debt -364.91Cr -313.24Cr -293.26Cr -268.53Cr -505.86Cr -35TCr -507.29Cr -3.47TCr -1.36TCr -18TCr -1.37TCr -1.34TCr -58TCr -219.36Cr -188.3Cr -176.29Cr -161.43Cr -304.1Cr -21TCr -304.96Cr -2.09TCr -816.05Cr -11TCr -823.6Cr -805.81Cr -35TCr
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
28/26/28 $142.77 -4.60% 2,49,22,736
26/26/26 $149.66 -5.77% 2,20,09,462
25/26/25 $158.83 +14.36% 4,92,25,650
24/26/24 $138.89 -4.30% 3,15,87,240
21/26/21 $145.13 +8.86% 8,73,16,065
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
149.66USD
Average target price
100.44USD
Spread / Average Target
-32.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock